Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbohydrate malabsorption following acarbose administration

H Sobajima1, M Mori, T Niwa

  • 1Department of Internal Medicine, Ogaki Municipal Hospital, Ogaki-city, Gifu Prefecture, Japan.

Diabetic Medicine : a Journal of the British Diabetic Association
|June 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Ring syndrome" involving chromosome 2 confirmed by FISH analysis using chromosome-specific subtelomeric probes.

Genetic counseling (Geneva, Switzerland)·2005
Same author

Relapse of neonatal herpes simplex virus infection.

Archives of disease in childhood. Fetal and neonatal edition·2003
Same author

Cloning, sequencing, and expression of the gene encoding 4-hydroxy-4-methyl-2-oxoglutarate aldolase from Pseudomonas ochraceae NGJ1.

Bioscience, biotechnology, and biochemistry·2002
Same author

Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.

Pharmacology·2001
Same author

Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.

Nephron·2000
Same author

Maternity blues and attachment to children in mothers of full-term normal infants.

Acta psychiatrica Scandinavica·2000

Acarbose reduces carbohydrate malabsorption in a dose-dependent manner. Continued use of acarbose decreased malabsorption in diabetic patients, maintaining stable glycemic control.

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Acarbose is an alpha-glucosidase inhibitor used to manage type 2 diabetes.
  • Understanding its effects on carbohydrate absorption is crucial for optimizing treatment.

Purpose of the Study:

  • To investigate the impact of acarbose on carbohydrate absorption in healthy volunteers and patients with type 2 diabetes.
  • To determine the dose-dependency and duration effects of acarbose on carbohydrate malabsorption.

Main Methods:

  • Healthy volunteers received lactulose, and breath hydrogen levels were monitored to assess carbohydrate absorption.
  • Dose-response effects of acarbose were evaluated using Ensure Liquid in healthy subjects.
  • Type 2 diabetes patients were assessed for breath hydrogen excretion and HbA1c levels before and after acarbose administration over several months.

Related Experiment Videos

Main Results:

  • Acarbose administration led to increased unabsorbed carbohydrate in a dose-dependent manner (50mg and 100mg doses).
  • In diabetic patients, acarbose significantly reduced carbohydrate malabsorption by 31.6% after 2 months.
  • Despite reduced malabsorption, HbA1c levels remained stable in diabetic patients after 5 months of acarbose treatment.

Conclusions:

  • The degree of carbohydrate malabsorption induced by acarbose is influenced by both the drug dosage and the carbohydrate load.
  • Sustained acarbose administration effectively reduces carbohydrate malabsorption.
  • Acarbose treatment aids in maintaining glycemic control in patients with type 2 diabetes mellitus.